Jade Biosciences (JBIO) Cash from Operations (2020 - 2026)
Jade Biosciences (JBIO) posted Cash from Operations of 24100000.0 for Q1 2026, up 28.4% on a QoQ basis from 33660000.0 in Q4 2025, and down 28.49% year-over-year from 33699396.15 in Q1 2025.
Jade Biosciences (JBIO) Cash from Operations (2020 - 2026) Analysis & Trends
Jade Biosciences' Cash from Operations history runs 7 years deep, the most recent figure standing at 24100000.0 for Q1 2026.
- Quarterly Cash from Operations fell 28.49% year-over-year to 24100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 100043000.0 (down 107.67% YoY) and the FY2025 annual result came in at 94700000.0, down 33.01% from the prior year.
- Cash from Operations was 24100000.0 for Q1 2026 at Jade Biosciences, up from 33660000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 5661000.0 in Q1 2022 and bottomed at 33660000.0 in Q4 2025.
- A 5-year average of 16736812.5 and a median of 15277000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 56.43% — and 2025, when it sank 225.26%.
- Jade Biosciences' Cash from Operations stood at 14865000.0 in 2022, then climbed by 0.44% to 14800000.0 in 2023, then slumped by 52.8% to 22614000.0 in 2024, then tumbled by 48.85% to 33660000.0 in 2025, then increased by 28.4% to 24100000.0 in 2026.
- Business Quant data shows JBIO's Cash from Operations at 24100000.0 in Q1 2026, 33660000.0 in Q4 2025, and 22124000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Jade Biosciences | 16.25 Mn | 16.25 Mn | - | -24.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.10 Mn |
| Mar 31, 2026 | -24.10 Mn |
| Dec 31, 2025 | -33.66 Mn |
| Dec 31, 2025 | -33.66 Mn |
| Sep 30, 2025 | -22.12 Mn |
| Sep 30, 2025 | -22.12 Mn |
| Jun 30, 2025 | -20.16 Mn |
| Jun 30, 2025 | -20.16 Mn |
| Mar 31, 2025 | -18.76 Mn |
| Mar 31, 2025 | -18.76 Mn |
| Dec 31, 2024 | -22.61 Mn |
| Dec 31, 2024 | -22.61 Mn |
| Sep 30, 2024 | -6.80 Mn |
| Sep 30, 2024 | -6.80 Mn |
| Mar 31, 2024 | -23.67 Mn |
| Mar 31, 2024 | -23.67 Mn |
| Dec 31, 2023 | -14.80 Mn |
| Dec 31, 2023 | -14.80 Mn |
| Sep 30, 2023 | -15.61 Mn |
| Sep 30, 2023 | -15.61 Mn |